Trans-arterial radioembolization with yttrium-90 microspheres (TARE with Y90) is a treatment for patients with liver cancers, but requires the evaluation of lung shunting fraction (LSF). Currently, LSF is estimated using a separate invasive “dry-run” with a transient radioactive Technetium-99m macroaggregated albumin (Tc-99m-MAA) that doubles the cost and risk of TARE. This study proposes to predict LSF from dynamic contrast enhanced MRI (DCE MRI) and perfusion quantification. Our preliminary data demonstrated that it is feasible to estimate LSF as measured by Tc-99m-MAA from noninvasive DCE MRI using quantitative transport mapping (QTM) velocity.
This abstract and the presentation materials are available to members only; a login is required.